Hormonal
Once-weekly subcutaneous dulaglutide (1.5 mg) is administered to patients with type 2 diabetes to evaluate its effect on cardiovascular outcomes, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
This paper outlines the design of the REWIND trial, which tests whether once-weekly dulaglutide (1.5 mg) reduces cardiovascular events (heart attack, stroke, cardiovascular death) in people with type 2 diabetes who are at high risk. The trial includes nearly 10,000 participants with a mean age of 66, many of whom have prior cardiovascular disease or risk factors. The results of this trial will help determine if dulaglutide is an effective cardiovascular protective agent for this population.
randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo... The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal MI or nonfatal stroke.
Why this rating
This is a rigorously designed, large-scale, randomized, placebo-controlled trial (REWIND) with a large sample size (n=9901) and international scope, representing high-quality evidence design, although results are pending.
Source
Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide
Hertzel C. Gerstein et al. · Diabetes Obesity and Metabolism · 2017
DOI 10.1111/dom.13028
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →